Tanemura M, Miyoshi E, Nagano H, Eguchi H, Matsunami K, Taniyama K, Hatanaka N, Akamatsu H, Mori M, Doki Y. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction. World J Gastroenterol 2015; 21(40): 11396-11410 [PMID: 26523105 DOI: 10.3748/wjg.v21.i40.11396]
Corresponding Author of This Article
Masahiro Tanemura, MD, PhD, Department of Surgery, Osaka Police Hospital, 10-31 Kitayamacho Tennoujiku, Osaka 543-0035, Japan. tanemuram@oph.gr.jp
Research Domain of This Article
Immunology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tanemura M, Miyoshi E, Nagano H, Eguchi H, Matsunami K, Taniyama K, Hatanaka N, Akamatsu H, Mori M, Doki Y. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction. World J Gastroenterol 2015; 21(40): 11396-11410 [PMID: 26523105 DOI: 10.3748/wjg.v21.i40.11396]
Masahiro Tanemura, Hiroki Akamatsu, Department of Surgery, Osaka Police Hospital, 10-31 Kitayamacho Tennoujiku, Osaka 543-0035, Japan
Eiji Miyoshi, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
Hiroaki Nagano, Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Yamaguchi 755-8505, Japan
Hidetoshi Eguchi, Masaki Mori, Yuichiro Doki, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
Katsuyoshi Matsunami, Department of Pharmacognosy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734–8553, Japan
Kiyomi Taniyama, Nobutaka Hatanaka, Department of Surgery and Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan
Author contributions: Tanemura M, Nagano H and Miyoshi E designed the research; Eguchi H and Matsunami K performed the research; Tanemura M wrote the paper; Mori M and Doki Y critically reviewed the paper; Taniyama K, Hatanaka N and Akamatsu H critically revised the paper.
Supported by Ministry of Education, Sports and Culture of Japan to M. T., No. 25462129.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Correspondence to: Masahiro Tanemura, MD, PhD, Department of Surgery, Osaka Police Hospital, 10-31 Kitayamacho Tennoujiku, Osaka 543-0035, Japan. tanemuram@oph.gr.jp
Telephone: +81-6-67716051 Fax: +81-6-67752838
Received: May 4, 2015 Peer-review started: May 9, 2015 First decision: June 2, 2015 Revised: July 2, 2015 Accepted: August 30, 2015 Article in press: August 31, 2015 Published online: October 28, 2015 Processing time: 171 Days and 23.9 Hours
Core Tip
Core tip: The goal of cancer immunotherapy is to elicit an immune response against autologous tumors and to induce multiple T cell clones against multiple tumor-associated antigens. To establish effective, next-generation immunotherapy toward pancreatic ductal adenocarcinoma (PDAC), we focus on the strong interaction between the natural human antibody, anti-Gal, and carbohydrate antigens called “α-gal epitopes”. Here, we review the literature on the distribution of natural anti-Gal antibody and its ligand in mammals and characterization of the immunosuppressive microenvironment of PDAC tumors, which is a major obstacle against effective clinical immunotherapies. We also discuss immunotherapeutic strategies using the α-gal epitope/anti-Gal antibody reaction.
